Belite Bio Inc ADR (BLTE)

$169.02 +3.38 (2.04%)
Market Cap 6.21B
Revenue (ttm) 0.00
Net Income (ttm) -36.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 356,000
Avg Vol 260,788
Day's Range N/A - N/A
Shares Out 37.52M
Stochastic %K 78%
Beta -1.46
Analysts Strong Sell
Price Target $186.50

Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 246 6240
Address:
12750 High Bluff Drive, Suite 475, San Diego, United States
SuperGreenToday
SuperGreenToday Jan. 30 at 4:40 AM
$BLTE
0 · Reply
IN0V8
IN0V8 Jan. 29 at 4:22 PM
$BLTE 1/28/26 Opportunity Leerink Partners raises target price to $185 from $140
0 · Reply
erevnon
erevnon Jan. 26 at 12:23 PM
B of A Securities initiates coverage on Belite Bio $BLTE at Buy rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
BioTechHealthX
BioTechHealthX Jan. 25 at 4:44 PM
$BLTE Belite Bio (NASDAQ:BLTE) is emerging as one of the most talked-about retinal disease biotech stocks as its Phase 3 program advances and commercialization plans take shape. Here’s why investors are suddenly paying attention. https://biotechhealthx.com/uncategorized/is-belite-bio-blte-quietly-building-a-billion-dollar-future/
0 · Reply
CrazyRick7
CrazyRick7 Jan. 14 at 12:42 AM
$BLTE core focus is on Tinlarebant, a clinical-stage therapeutic aimed at retinal degenerative diseases with significant unmet need. Progress in Phase 3 trials and potential regulatory success could vastly increase valuation if approved…
0 · Reply
CrazyRick7
CrazyRick7 Jan. 14 at 12:41 AM
$BLTE Strong Analyst Ratings & Upside Potential
0 · Reply
CrazyRick7
CrazyRick7 Jan. 14 at 12:41 AM
$BLTE
0 · Reply
WAJeff
WAJeff Dec. 29 at 9:41 PM
$BLTE 12/24 156s sold 162.98
0 · Reply
DwarfPlanetDye
DwarfPlanetDye Dec. 27 at 4:38 AM
$BLTE Positioning is increasingly shaped by how predictably management executes. Margins must hold as the company navigates cost pressure. Execution consistency is the fastest path to confidence rebuilding. Ultimately, disciplined delivery will shape the outcome.
0 · Reply
topstockalerts
topstockalerts Dec. 17 at 5:24 PM
$BLTE heating up…👀
0 · Reply
Latest News on BLTE
Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares

Dec 1, 2025, 10:37 PM EST - 2 months ago

Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares

Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares

Dec 1, 2025, 4:20 PM EST - 2 months ago

Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares

Belite Bio, Inc (BLTE) Discusses Positive Topline Results from Phase III DRAGON Trial of Tinlarebant in Stargardt Disease Transcript

Dec 1, 2025, 2:23 PM EST - 2 months ago

Belite Bio, Inc (BLTE) Discusses Positive Topline Results from Phase III DRAGON Trial of Tinlarebant in Stargardt Disease Transcript

Belite Bio Scores First Successful Phase 3 Trial For Rare Vision-Loss Disease

Dec 1, 2025, 9:14 AM EST - 2 months ago

Belite Bio Scores First Successful Phase 3 Trial For Rare Vision-Loss Disease

Belite Bio's drug for genetic eye disease meets main goal in late-stage trial

Dec 1, 2025, 6:09 AM EST - 2 months ago

Belite Bio's drug for genetic eye disease meets main goal in late-stage trial

New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease

Dec 1, 2025, 6:00 AM EST - 2 months ago

New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease

Belite Bio, Inc (BLTE) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 6:11 PM EST - 2 months ago

Belite Bio, Inc (BLTE) Q3 2025 Earnings Call Transcript

Belite Bio, Inc (BLTE) Presents at Deutsche Bank ADR Virtual Investor Conference 2025 Prepared Remarks Transcript

Nov 4, 2025, 12:36 PM EST - 3 months ago

Belite Bio, Inc (BLTE) Presents at Deutsche Bank ADR Virtual Investor Conference 2025 Prepared Remarks Transcript

Belite Bio to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference November 4th

Oct 29, 2025, 8:35 AM EDT - 3 months ago

Belite Bio to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference November 4th

Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference

Oct 29, 2025, 8:00 AM EDT - 3 months ago

Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference

Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

Oct 15, 2025, 8:00 AM EDT - 3 months ago

Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease

Sep 12, 2025, 8:00 AM EDT - 4 months ago

Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease

Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors

Sep 8, 2025, 8:00 AM EDT - 5 months ago

Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors

Belite Bio, Inc (BLTE) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 11:36 PM EDT - 6 months ago

Belite Bio, Inc (BLTE) Q2 2025 Earnings Call Transcript

Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Aug 11, 2025, 6:00 AM EDT - 6 months ago

Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Belite Bio Announces Registered Direct Offering of $15 Million

Aug 7, 2025, 8:00 AM EDT - 6 months ago

Belite Bio Announces Registered Direct Offering of $15 Million

Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

Jul 2, 2025, 3:00 AM EDT - 7 months ago

Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease

May 21, 2025, 3:00 AM EDT - 9 months ago

Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease

Belite Bio: Investors Face Tricky Decision Ahead Of Key STGD1 Study Readout

May 15, 2025, 11:53 AM EDT - 9 months ago

Belite Bio: Investors Face Tricky Decision Ahead Of Key STGD1 Study Readout

Belite Bio, Inc (BLTE) Q1 2025 Earnings Call Transcript

May 15, 2025, 4:59 AM EDT - 9 months ago

Belite Bio, Inc (BLTE) Q1 2025 Earnings Call Transcript

Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025, 9:00 PM EDT - 9 months ago

Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

Belite Bio, Inc to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference May 15th

May 12, 2025, 8:35 AM EDT - 9 months ago

Belite Bio, Inc to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference May 15th

Belite Bio to Participate in Four Upcoming Investor Conferences

May 12, 2025, 8:00 AM EDT - 9 months ago

Belite Bio to Participate in Four Upcoming Investor Conferences

Belite Bio, Inc. (BLTE) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 6:40 PM EDT - 11 months ago

Belite Bio, Inc. (BLTE) Q4 2024 Earnings Call Transcript

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

Mar 17, 2025, 6:00 AM EDT - 11 months ago

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 17, 2025, 6:00 AM EDT - 11 months ago

Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Mar 11, 2025, 3:00 AM EDT - 11 months ago

Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007

Nov 27, 2024, 3:00 AM EST - 1 year ago

Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007

Belite Bio, Inc. (BLTE) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 8:28 PM EST - 1 year ago

Belite Bio, Inc. (BLTE) Q3 2024 Earnings Call Transcript

Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results

Nov 5, 2024, 8:00 AM EST - 1 year ago

Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results

Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

Nov 3, 2024, 4:00 PM EST - 1 year ago

Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

Sep 1, 2024, 8:00 AM EDT - 1 year ago

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

Belite Bio, Inc (BLTE) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 10:35 PM EDT - 1 year ago

Belite Bio, Inc (BLTE) Q2 2024 Earnings Call Transcript

Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Aug 9, 2024, 4:30 PM EDT - 1 year ago

Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results

Aug 5, 2024, 7:10 PM EDT - 1 year ago

Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results

Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan

Jun 12, 2024, 2:55 AM EDT - 1 year ago

Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan

Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript

May 14, 2024, 8:11 PM EDT - 1 year ago

Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript

Belite Bio to Participate in the Benchmark's 4th Annual Healthcare House Call Investor Conference

May 14, 2024, 8:00 AM EDT - 1 year ago

Belite Bio to Participate in the Benchmark's 4th Annual Healthcare House Call Investor Conference

Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update

May 13, 2024, 9:50 PM EDT - 1 year ago

Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update

Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 13, 2024, 8:00 AM EDT - 1 year ago

Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results

May 8, 2024, 8:00 AM EDT - 1 year ago

Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results

Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant

May 6, 2024, 8:15 AM EDT - 1 year ago

Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant

Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting

May 6, 2024, 8:00 AM EDT - 1 year ago

Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting

Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

May 1, 2024, 4:15 PM EDT - 1 year ago

Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

Belite Bio Announces $25 Million Registered Direct Offering

Apr 25, 2024, 7:15 PM EDT - 1 year ago

Belite Bio Announces $25 Million Registered Direct Offering

Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan

Mar 22, 2024, 8:00 AM EDT - 2 years ago

Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan

Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript

Mar 12, 2024, 7:53 PM EDT - 2 years ago

Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

Mar 11, 2024, 10:28 PM EDT - 2 years ago

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 11, 2024, 9:27 PM EDT - 2 years ago

Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

SuperGreenToday
SuperGreenToday Jan. 30 at 4:40 AM
$BLTE
0 · Reply
IN0V8
IN0V8 Jan. 29 at 4:22 PM
$BLTE 1/28/26 Opportunity Leerink Partners raises target price to $185 from $140
0 · Reply
erevnon
erevnon Jan. 26 at 12:23 PM
B of A Securities initiates coverage on Belite Bio $BLTE at Buy rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
BioTechHealthX
BioTechHealthX Jan. 25 at 4:44 PM
$BLTE Belite Bio (NASDAQ:BLTE) is emerging as one of the most talked-about retinal disease biotech stocks as its Phase 3 program advances and commercialization plans take shape. Here’s why investors are suddenly paying attention. https://biotechhealthx.com/uncategorized/is-belite-bio-blte-quietly-building-a-billion-dollar-future/
0 · Reply
CrazyRick7
CrazyRick7 Jan. 14 at 12:42 AM
$BLTE core focus is on Tinlarebant, a clinical-stage therapeutic aimed at retinal degenerative diseases with significant unmet need. Progress in Phase 3 trials and potential regulatory success could vastly increase valuation if approved…
0 · Reply
CrazyRick7
CrazyRick7 Jan. 14 at 12:41 AM
$BLTE Strong Analyst Ratings & Upside Potential
0 · Reply
CrazyRick7
CrazyRick7 Jan. 14 at 12:41 AM
$BLTE
0 · Reply
WAJeff
WAJeff Dec. 29 at 9:41 PM
$BLTE 12/24 156s sold 162.98
0 · Reply
DwarfPlanetDye
DwarfPlanetDye Dec. 27 at 4:38 AM
$BLTE Positioning is increasingly shaped by how predictably management executes. Margins must hold as the company navigates cost pressure. Execution consistency is the fastest path to confidence rebuilding. Ultimately, disciplined delivery will shape the outcome.
0 · Reply
topstockalerts
topstockalerts Dec. 17 at 5:24 PM
$BLTE heating up…👀
0 · Reply
Doozio
Doozio Dec. 17 at 2:13 AM
$BLTE out of the HTF…..
0 · Reply
Doozio
Doozio Dec. 11 at 3:20 PM
$BLTE if no faatch 💣 lands?
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 10 at 2:01 AM
$BLTE Current Stock Price: $149.34
0 · Reply
crazysnake
crazysnake Dec. 9 at 4:00 PM
$OCGN can patients do the ocu procedure and take $BLTE pills for GA and stagart they could take a big chunk of the market since they are going to get approved 3 years before ocu410st thinking about going back to pstv since its on steady climb
0 · Reply
NetworkNewsWire
NetworkNewsWire Dec. 5 at 5:04 PM
InvestorNewsBreaks – $BLTE Prices $350M Underwritten Public Offering of ADSs https://ibn.fm/aSit4
0 · Reply
IN0V8
IN0V8 Dec. 3 at 3:45 PM
$BLTE Watch / Buy Benchmark raises target price to $187 from $132 Maxim Group raises target price to $200 from $140
0 · Reply
SilverEagle
SilverEagle Dec. 3 at 3:12 PM
$BLTE yeah. Multiple hulks.
0 · Reply
CaptSparow
CaptSparow Dec. 3 at 3:30 AM
$OCGN BTW, when Ocugen hits, it should be a violent upside imho. $BLTE used as comparable.
1 · Reply
CaptSparow
CaptSparow Dec. 3 at 3:18 AM
$BLTE Congrats on Belite Bio 5 year chart. Early birds get the worm! Keep an eye on Ocugen for a likewise replication.
0 · Reply
RunnerSignals
RunnerSignals Dec. 2 at 8:20 PM
$BLTE $CDRE $CEVA $CHYM $CNTB Some serious fireworks here also! https://stocksrunner.com/news/2025-12-02-stock-upgrades-today-highlight-top-picks
0 · Reply
erevnon
erevnon Dec. 2 at 3:21 PM
Mizuho upgrades Belite Bio $BLTE from Neutral to Outperform and raises the price target from $105 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
JarvisFlow
JarvisFlow Dec. 2 at 3:05 PM
Mizuho has updated their rating for Belite Bio ( $BLTE ) to Outperform with a price target of 194.
0 · Reply